Valneva SE: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Pat Volpe Steps Down As Chairman Of Cardia Bioplastics Ltd
Cardia Bioplastics Ltd announced that Mr. Pat Volpe has stepped down from his role as Chairman of Cardia due to other work commitments. Mr. Richard Tegoni will assume the role of Non-Executive Chairman, effective immediately.
Latest Developments for Valneva SE
- Valneva SE announces first ever marketing approval in Europe for vaccine produced in EB66 cell line
- Valneva SE announces first marketing authorization for human vaccine produced in EB66 cell line
- Valneva SE announces approval and launch in South America of second veterinary vaccine produced in EB66 cell line
- Valneva SE issues FY 2014 revenue guidance
- Share this
- Digg this